Ascletis Announces Phase III Trial of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne, Meets All Endpoints

[
Ascletis Announces Phase III Trial of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne, Meets All Endpoints
[og_img]
https://www.investing.com/news/press-releases/ascletis-announces-phase-iii-trial-of-denifanstat-asc40-a-firstinclass-oncedaily-oral-fasn-inhibitor-for-acne-meets-all-endpoints-93CH-4079364


Investing.com